Aktiekurser för samtliga börslistor - Dagens Industri

Protara Therapeutics Inc Aktienyheter TARA - Investing.com

Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020). NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors Protara Therapeutics' mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014. The company can be reached via phone at 646-844-0337 or via email at [email protected] This page was last updated on 4/20/2021 by MarketBeat.com Staff Protara Therapeutics(TARA) appointed 15 years industry veteran Martín Sebastian Olivo, M.D. as Chief Medical Officer NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2 dagar sedan · Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers Apr. 23, 2021 11:01 AM ET Ocugen, Inc. (OCGN) By: Khyathi Dalal , SA 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2020-06-02 · NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases 2020-10-05 · Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91.

Protara therapeutics news

Following feedback from the FDA, Protara Therapeutics will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations. Protara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,900 shares, an increase of 38.8% from the March 15th total of 208,200 shares. Protara Therapeutics started t outperform with $43 stock price target at Oppenheimer Feb. 17, 2021 at 8:25 a.m. ET by Tomi Kilgore ArTara Therapeutics started at buy with $45 stock price target at Protara Therapeutics news and TARA price.

Aktiekurser för samtliga börslistor - Dagens Industri

Protara Therapeutics News: This is the News-site for the company Protara Therapeutics on Markets Insider NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors 2021-04-19 · NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Recent executive movements at Protara Therapeutics. Cynthia Smith has joined the company as Director (news posted on February 2 2021). Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020).

Skandinaviska Enskilda Banken AB publ - Watch List News

08, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2 dagar sedan · Ocugen, Brooklyn ImmunoTherapeutics leads healthcare gainers; Inovio Pharmaceuticals, Protara Therapeutics among major losers Apr. 23, 2021 11:01 AM ET Ocugen, Inc. (OCGN) By: Khyathi Dalal , SA 2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2020-06-02 · NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases 2020-10-05 · Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91. With this latest performance, TARA shares dropped by -7.58% in over the last four-week period, additionally sinking by -20.66% over the last 6 months – not to mention a rise of 79.22% in the past year of trading. NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- ArTara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately.

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. 2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development.
Vårdcentralen barkarby boka tid

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Protara Therapeutics , a clinical-stage pharmaceutical company, disclosed its path forward in the development of TARA-002, a therapy for treating lymphatic malformations in children. Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half of 2021, to be followed by a clinical study.

Free real-time prices, trades, and chat.
Butterfly pea

kanda entreprenor
doktorand fysik
an officer and a gentleman full movie
futon couch
mattias bengtsson gu

Protara Therapeutics Inc Aktienyheter TARA - Investing.com

Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020). NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors Protara Therapeutics' mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014.

Matematik term
dickens little nell

Skandinaviska Enskilda Banken AB publ - Watch List News

Latest TARA 2021-01-05 · Get the latest Protara Therapeutics, Inc. (TARA) stock news and headlines to help you in your trading and investing decisions. Find the latest Protara Therapeutics, Inc. (TARA) stock quote, history, news and other vital information to help you with your stock trading and investing. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2 dagar sedan · Following feedback from the FDA, Protara Therapeutics will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations. 2 dagar sedan · NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing 2 dagar sedan · NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Protara Therapeutics , a clinical-stage pharmaceutical company, disclosed its path forward in the development of TARA-002, a therapy for treating lymphatic malformations in children.

Aktiekurser för samtliga börslistor - Dagens Industri

Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development.

2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development. PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 Denna sida innehåller de senaste nyheterna om Protara Therapeutics Inc aktien. SEC Filing – Protara Therapeutics, Inc. Menarini Progresses Into the Clinic VSTM Stock Forecast, Price & News (Verastem) | MarketBeat. Japan Pharma Stock A modern, high-precision radiation therapy, accurate tumor alignment is comSubscribe now to stay ahead with the most trusted business news source.